Company Description
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.
It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps.
It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.
The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.
Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2005 |
| IPO Date | May 1, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Dr. Maria Palasis Ph.D. |
Contact Details
Address: 480 Arsenal Way Watertown, Massachusetts 02472 United States | |
| Phone | 617-373-4600 |
| Website | lyratherapeutics.com |
Stock Details
| Ticker Symbol | LYRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001327273 |
| CUSIP Number | 55234L105 |
| ISIN Number | US55234L1052 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harlan W. Waksal M.D. | Executive Chairman |
| Dr. Maria Palasis Ph.D. | Chief Executive Officer, President and Director |
| Dr. John E. Bishop Ph.D. | Chief Technology Officer |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder |
| Jason Cavalier | Chief Financial Officer, Treasurer and Secretary |
| Ray Knox | Vice President of Operations |
| Ellen Cavaleri | Senior Vice President of Investor Relations and Communications |
| Ronan P. O'Brien J.D. | Chief Legal Officer |
| Corinne Noyes | Senior Vice President of Commercial Strategy and Market Development |
| Vineeta Belanger Ph.D. | Senior Vice President of Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 19, 2024 | 8-K | Current Report |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Mar 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 22, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |